Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 83 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 84 The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran
Skip Navigation
Skip to contents

Epidemiol Health : Epidemiology and Health



Page Path
HOME > Epidemiol Health > Volume 40; 2018 > Article
Original Article
The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran
Alireza Ansari-Moghaddam1orcid, Hossein Ali Adineh2orcid, Iraj Zareban3orcid, Mehdi Mohammadi1orcid, Mahtab Maghsoodlu4orcid
Epidemiol Health 2018;40:e2018048.
DOI: https://doi.org/10.4178/epih.e2018048
Published online: October 3, 2018
  • 278 Download
  • 21 Web of Science
  • 20 Crossref
  • 18 Scopus

1Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

2Department of Epidemiology and Biostatistics, Iranshahr University of Medical Sciences, Iranshahr, Iran

3Department of Health Education, Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

4Research Center, Iran Blood Transfusion Organization, Tehran, Iran

Correspondence: Hossein Ali Adineh  Department of Epidemiology and Biostatistics, Iranshahr University of Medical Sciences, Iranshahr 9916643535, Iran  E-mail: payam.health@yahoo.com
• Received: June 25, 2018   • Accepted: October 3, 2018

©2018, Korean Society of Epidemiology

This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    Thalassemia is a common genetic disease in Iran, especially in the north and south of Iran. The present study sought to determine the survival rate of patients with thalassemia in highly endemic regions of Iran and its variation in patients born before and after 1971.
    The present historical cohort study extracted data from the health records of patients with beta-thalassemia major, beta-thalassemia intermedia, and sickle beta-thalassemia who had presented to thalassemia treatment centers in the past years. The collected data were analyzed using the Kaplan-Meier test, the log-rank test, and the chi-square test.
    Of the total of 5,491 medical records (2,647 men and 2,634 women; mean age, 23.81±11.32 years), 3,936 belonged to patients with beta-thalassemia major, and 999 and 89 to patients with beta-thalassemia intermedia and sickle beta-thalassemia, respectively. In 467 cases, the type of thalassemia was not clear. The cumulative survival rate was calculated as 0.92, 0.83, 0.74, and 0.51 by ages 25, 35, 45, and 55, respectively. The hazard ratio of death was 4.22 (p<0.05) for beta-thalassemia major and 0.77 for beta-thalassemia intermedia (p=0.70). It was calculated as 1.45 for men patients and as 3.82 for single patients.
    The present study showed relatively high survival rates in patients with thalassemia. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including women gender, a higher level of education, being married, and living in metropolises decreased the risk of death at younger ages and improved survival.
Beta-thalassemia is an inherited hemoglobin disorder in the beta-globin chain that results in chronic hemolytic anemia. Two major forms of beta-thalassemia have been identified according to their clinical severity [1,2]. Thalassemia major (TM) manifests with severe anemia in the first year of life in newborns, while thalassemia intermedia (TI) involves clinically asymptomatic mild anemia [3]. In developing and underdeveloped countries, patients with TM die in childhood and adolescence due to the lack of public access to blood transfusions tested for viruses and timely iron removal from the body [4]. The underlying causes of death in patients with TM include iron overload and excess serum ferritin [5], which lead to cardiac disease, liver and endocrine disorders, infection, thrombosis, anemia, malignancy, and eventually death [6-9].
In the long term, untreated TI causes gallstones, pulmonary hypertension, thrombophilia, osteoporosis, and foot ulcers [10-12]. These symptoms are rare in patients with TM. Untreated TI causes cardiac problems in the fourth decade of life through hypoxia and increased pulmonary resistance, potentially leading to death [1,11,13-15].
Beta-thalassemia is widely prevalent across the Mediterranean region, Africa, and the Middle East (including Iran), and the prevalence of the mutation reaches 3 to 10% in some of these regions [2]. In Iran, beta-thalassemia is the most common form [16]; the disorder is most common along the coast of the Persian Gulf and the Caspian Sea, with a prevalence of more than 10% [17,18].
Although the prognosis and survival of thalassemia patients are improving across the world [19] and in Iran (based on results of some local studies), the prevalence of complications remains high in those affected [20-22], and cardiac disease remains the main cause of death in patients with high ferritin levels [23]. Variations in the prognosis of thalassemia patients may be due to the development of new treatments, such as bone marrow transplant or splenectomy in TI patients [7,10,24,25], or due to certain new causes of death, such as human immunodeficiency virus and hepatitis C [7].
Given the variations in the prognosis of the disease, obtaining adequate reliable information about common complications that affect the trend and prognosis of the disease in patients treated with conventional or modern methods in different regions of Iran is essential for planning and making decisions about genetic consultations and bone marrow transplantations in affected children [26].
The present study was conducted to determine the survival rate of patients with TM, TI, and sickle-thalassemia in highly endemic regions of Iran and to examine the effects of the main factors associated with survival in patients with TM and TI.
The present historical cohort study was conducted to determine the survival rate of patients with thalassemia born before 1971 and those born from 1971 to 2015 in Sistan and Baluchestan (Zahedan and Iranshahr), Hormozgan (Center for Special Diseases of Shahid Mohammadi Hospital), Tehran, and Mazandaran (Sari) Provinces. In Iran, the northern and southern provinces have highest frequency of thalassemia, and there are referral hospitals in the selected provinces that accept all patients from around the areas of the referral hospitals. Therefore, based on the prevalence of thalassemia and the existence of referral hospitals/centers, we selected 2 high-prevalence provinces from the north (Tehran and Mazandaran) and 2 provinces (Sistan and Baluchestan [Zahedan and Iranshahr] and Hormozgan) from the south of Iran. People with symptoms of anemia are screened for thalassemia at health provider centers, and patients suffering from thalassemia are referred to centers that provide medical services for thalassemia patients. The study population consisted of patients with TM, TI, and sickle beta-thalassemia that had medical records at the thalassemia units and were receiving medical services from them. Patients who had not presented to these medical centers in the 2 years preceding the study or who had incomplete or no records were excluded from the study.
Data about the form of thalassemia, the date of diagnosis, the initiation of iron removal from the body, and age were extracted from the patients’ records, along with some other required information. Trained investigators who were familiar with medical records visited the referral centers for thalassemia in each province, selected the records of all patients admitted from the inauguration of the center until 2015, and extracted the patients’ demographic details, such as age, gender, family history of thalassemia, date of diagnosis, and date of initiation of treatment. Certain outcomes, such as the date of death after the diagnosis of thalassemia, were determined by referring to the patients’ health records or the hospital archivists, or by asking their physicians. Subjects without valid and secure evidence of their death were considered to still be alive.
The present study examined the health records of a total of 5,491 patients from Tehran (n=2,717), Sari (n=739), Bandar-e-Abbas (Hormozgan) (n=815), Iranshahr (n=599), and Zahedan (n=621) using the consensus method (Figure 1).
Thalassemia is prevalent in the southern and northern regions of Iran. Due to the high frequency of thalassemia and the distances between cities, thalassemia patients are referred to a central hospital in each province. In the present study, all medical records from the selected provinces in the south of Iran (Hormozgan, Zahedan, and Iranshahr) and the north of Iran (Tehran and Mazandaran) were assessed to analyze the survival rate. It should be noted that Iranshahr and Zahedan are the 2 major cities in Sistan and Baluchestan Province; Iranshahr is located in the south and Zahedan in the north of the province.
Data entry and analysis
The extracted data from the patients’ records were entered into a pre-developed checklist and then transferred to Microsoft Excel 2010 (Microsoft, Redmond, WA, USA). The survival duration of each participant was obtained by subtracting the date of birth from the date of death. The survival rate of thalassemia patients was determined using the Kaplan-Meier test; this rate was compared between the different groups using the log-rank test. Trends in patient survival over the defined period were demonstrated using Kaplan-Meier curves. We carried out a Cox regression model to determine the effect of some factors on the survival of patients; these variables were separately entered into the model. We used a significance level of 0.05 and 95% confidence intervals (CIs). The relationship between the categorical variables was assessed using the chi-square test. All the analyses were performed in SPSS version 22.0 (IBM Corp., Armonk, NY, USA).
Ethics statements
The present study was examined and approved by the ethics committee of Zahedan University of Medical Sciences. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
The present study examined 5,491 health records (2,647 [48.2%] from men and 2,634 [48.0%] from women, and 210 (3.8%) cases did not have available medical records). The mean age of the thalassemia patients was estimated as 23.81±11.32 years; it was very similar in Tehran and Sari (28.53 vs. 28.12 years), but was lower in Bandar-e-Abbas (Hormozgan) and Zahedan (18.92 and 15.88 years). Iranshahr had the youngest population of thalassemia patients, with a mean age of 11.39, which was lower than in the other cities.
The plurality of medical records (n=2,717, 49.5%) were obtained from Tehran, the capital of Iran. Additionally, 739 (13.5%) records were obtained from Sari, 815 (14.8%) from Bandar-e-Abbas (Hormozgan), 621 (11.3%) from Zahedan, and 599 (10.9%) from Iranshahr. By type of thalassemia, 3,936 (71.7%) belonged to patients with TM, 999 (2.2%) to patients with TI, and 89 (1.6%) to patients with sickle beta-thalassemia. The form of thalassemia could not be determined in 467 (8.5%) cases due to illegible, outdated, or incomplete records. In terms of the level of education, more than 60% of the TM patients, 50% of those with TI, and 70% of those with sickle beta-thalassemia had less than a high school education. Overall, 1,091 (22.5%) patients were illiterate, 1,947 (40.0%) had less than a high school education, 995 (20.5%) had a high school diploma, and 826 (17.0%) had above a high school education. Iranshahr, among the poorest cities in Iran, had the highest percentage of illiterate patients (54.5%), followed by Zahedan (19.6%) and Tehran (14.8%). Sari had the lowest number of illiterate patients (0.1%), followed by Bandar-e-Abbas (Hormozgan) (0.1%). Overall, 79.4% of the thalassemia patients were single and 20.2% were married. According to the health records, 85.2% of the TM patients, 66.0% of the TI patients, and 73.1% of the sickle beta-thalassemia patients were single.
Our findings showed that 1,666 (30.3%) patients were blood relatives of their spouse, while 1,519 (27.7%) had no such relationship to their spouse. The ratio of patients who were related by blood to their spouse was similar for all the different forms of thalassemia; however, this ratio differed by city. In Zahedan, most thalassemia patients (72.1 vs. 27.9%) reported a blood relationship to their spouse; in Bandar-e-Abbas (Hormozgan), this ratio (56.7%) was lower than in Zahedan, but higher than in all the other cities examined; in Sari, it was 32.5% (vs. the 67.5% who were not related by blood to their spouse); in Tehran, it was 50.7% (vs. 49.2%) (Table 1).
Survival of thalassemia patients
Table 2 shows the survival of patients in 5-year intervals. The survival rate varied with the number of deaths in each age group, with the highest number of deaths occurring around age 45. The survival rate was calculated to be 0.92 in the 45-50 age group and as 0.75 in the 50-55 age group. The cumulative survival rate from birth until 10 years old was 99%. After reaching the age of 20 years, 88% of the patients survived until 30 years, 74% survived until 45, 68% survived until 50, and 51% survived until 55 years old. The age of 242 patients was inadvertently not extracted or had not been recorded.
The survival curve of patients born before and after 1971
Figure 2 presents the survival rate until various ages for patients born before and after 1971. As shown, 100% of the patients born before 1971 survived until age 35, and then their survival declined and dropped to 93% by age 45 and to 73% by age 55. In contrast, 100% of the patients born after 1971 survived until age 10, and then their survival dropped to 98% by age 15 and to 85% by age 35.
Estimated survival by form of thalassemia, place of residence, and gender
The mean estimated survival of thalassemia patients in Iran (Tehran, Mazandaran, Bandar-e-Abbas [Hormozgan], Zahedan and Iranshahr) was calculated as 52.42 years using the Kaplan-Meier test (95% CI, 51.61 to 53.23).
The rate of survival differed significantly between the patients with TM, TI, sickle, and unidentified thalassemia (p<0.001). The patients with TI tended to survive the longest (55.59 years; 95% CI, 55.65 to 57.52), followed by the patients with sickle beta-thalassemia (53.00 years; 95% CI, 50.54 to 55.66), while the patients with TM died earlier (50.07 years; 95% CI, 48.54 to 51.60). The form of thalassemia was not recorded in the checklist for a number of patients, whose mean age at death was calculated as 46.26 years, ranging from 43.08 to 49.44 years. Figure 3 and Table 3 show trends in survival by city and by form of thalassemia, respectively. The proportional hazard assumption was assessed by chi-square test and graphical plots, since the slight heterogeneity of variance that we observed in the relevant categories led to a slight violation of this assumption (p=0.06 and 0.07 for Figure 3).
Survival differed significantly across cities (p<0.001), with the patients from Tehran surviving longest and those from Iranshahr having the shortest survival (54.10 vs. 30.23 years). Following Tehran, the patients from Mazandaran survived longest (47.28 years). As shown in Table 3 and Figure 3, the patients from Zahedan (33.59 years) and Iranshahr (30.23 years) had the shortest survival. The log-rank test showed a significant difference in the mean survival rate between men and women (p=0.001). The mean survival was 53.49 years in women, which was lower than that in men (51.47 years).
Median survival by form of thalassemia and place of residence
The median survival was 58 years in the samples studied. This value differed across cities; it was 32 years in Zahedan, 54 in Mazandaran, 45 in Bandar-e-Abbas (Hormozgan) and 55 in Tehran. The median survival was 57 years in patients with TM, 55 in those with TI or sickle beta-thalassemia, and 49 in those with unidentified thalassemia (Table 3).
The effects of gender, city of residence, and form of thalassemia on the survival of thalassemia patients
The Cox regression test was used to examine the effects of gender, city of residence, and form of thalassemia on survival. The unadjusted hazard ratio (HR) was calculated for each variable. As shown in Table 4, Tehran was chosen as the reference group, and the HR for death was calculated for the remaining cities. The risk of death was higher in Zahedan and Iranshahr (6.25 and 5.42) than in Bandar-e-Abbas (Hormozgan) and Sari. The HR for death was also calculated for men and women; this ratio was higher in men than in women by 45% (p=0.001). Moreover, patients with TM had a higher risk of death than those with sickle beta-thalassemia (HR, 4.22), and the risk was lower in those with TI than in those with sickle beta-thalassemia (HR, 0.77). A low level of education also significantly affected the risk of death, as the HR for death was threefold higher in illiterate patients than in those with above a high school education (HR, 2.49; p=0.03). The corresponding HRs were 3.80 for patients with below a high school education and 1.80 for those with a high school diploma. Examining the unadjusted effect of marital status on the HR for death showed that single patients had a threefold higher risk of death than married patients (p<0.001). The number of widowed patients was very low in this study (n=4), and they were therefore excluded from the analysis; the HR for death was likewise not significant in divorced patients due to their low number. Despite the role of the discussed variables in increasing the HR for death, age at diagnosis, and date of initiation of iron removal from the body had an inverse relationship; in other words, they had a protective relationship with survival. The HR was calculated as 0.99 for the date of diagnosis and 1.00 for the initiation of iron removal from the body (p<0.001).
The present study examined 5,491 records of thalassemia patients. The overall mean and median survival of the patients were calculated as 52.42 and 58.00 years, respectively, which seem to be higher than the mean survival of patients reported in a study conducted only in Tehran (41.97 years) [27]. The higher overall survival in the present study may have been because of differences in survival across cities and according to the type of thalassemia. A significant difference was observed in the mean survival between men (51.47 years) and women (53.49 years), suggesting a longer survival in women, which is consistent with the results obtained in other studies; however, the mean survival reported for men and women in the present study is longer than has been reported in other studies [28]. The differences in the survival rates reported in various studies may be attributed to the smaller sample size used in the studies and calculating survival rate only in beta-thalassemia or intermedia thalassemia patients. The present study showed that 99% of the patients lived until 10, 97% until 15, 95% until 20, and 92% until 25 years old. The survival rates reported for these age intervals are higher than those reported in studies conducted in other parts of Iran (Shiraz, Hamadan, and Sistan and Baluchestan) [28-30]. In studies conducted by Zamani et al. [28] and Rajaeefard et al. [29], 88 and 85% of the patients lived until age 20, compared to the 95% rate reported in the present study. The improved patient survival in the present study may be explained by timely iron removal from the body and better patient care [31,32]. The survival rate to the age of 30 was estimated as roughly 41% in Ahvaz (a province in southwest Iran), which is lower than our estimation (88%), but this discrepancy may be explained by differences in patients’ place of residence [33]. Studies conducted in other countries over the last few years reported that the survival rate for thalassemia patients was 89% until the age of 20 and 82% until the age of 25 [26], which is similar to the results obtained in studies previously conducted in Iran; however, the rates may have gradually improved in recent years. Nonetheless, as shown in the survival curves, the patients born after 1971 showed a lower survival at older ages than those born before 1971; for instance, the survival rate was 99% until 40 years in patients born before 1971, compared to 85% in patients born after 1971. The reason for the lower survival of patients born in recent years is that we estimated the overall survival rate without adjusting for the place of residence. Since inhabitants of the south of Iran (Iranshahr and Zahedan) do not have enough access to health care and medical surveillance, their low survival rate affected the overall estimation of survival. In addition, our findings may have been affected by selection bias, in which patients with severe forms of disease may have died before being diagnosed and having medical records made; therefore, patients with better survival remained in the cohort born before 1971, whereas improvements in diagnostic tools might have led to diagnosis of the severe forms of thalassemia in patients born after 1971, resulting in a lower estimated survival. Furthermore, the level of access to health services and health literacy of patients may have contributed to differences in the survival rate. Before 1971, the disease registry in Iran was not as complete as after 1971. In that period of time, there was limited access to health services. Therefore, selected patients with good knowledge and perceptions of the disease, as well as relatively high socioeconomic conditions, may have been more likely to seek care in the health system.
The mean survival was 50.07 years for patients with TM and 56.59 and 53.10 years for patients with TI and sickle beta-thalassemia, respectively. TM patients appear to be at a greater risk of complications and death due to the severity of the disease and their higher need for transfusion and the subsequent iron overload in their body [11]. The mean survival of patients differed across cities, and the highest survival was observed in Tehran and the lowest in Iranshahr (54.10 vs. 30.23 years). It appears that patients residing in Tehran were in a better condition due to the early diagnosis of their disease, the earlier iron removal from their body, and the better care they received in the course of illness, while only 7 out of 590 patients and 27 out of 530 patients remained alive until 30 years old in Iranshahr and Zahedan, respectively. This suggests that patients in these cities receive later diagnoses and poorer care.
The survival of thalassemia patients is affected by various factors, including gender, which was examined in the present study. Although some studies have shown that the survival of patients was not affected by gender [33], others have confirmed the effect of gender on patient survival [26]. According to the present findings, the chances of death were 45% higher in men than in women, which is consistent with the results obtained in a study conducted in Hamadan [28]. The survival calculated in the life table and the Cox regression test showed that, in addition to men gender, having TM was associated with a higher risk of death compared to all other forms of the disease (HR, 4.22 for TM and 0.77 for TI). Patients with TM are at a higher risk of death due to their more critical condition, greater need for transfusion and the subsequent iron overload in their body, and various other complications. Another factor that indirectly affects the survival of thalassemia patients is their place of residence. In the present study, the risk of death in thalassemia patients was 5 and 6 times higher in Iranshahr and Zahedan than in Tehran (p<0.001). The risk of death was also 3.30 and 4.00 times higher in Sari and Bandar-e-Abbas (Hormozgan) than in Tehran (p<0.001). The differences in the survival rate across cities may have been due to differences in the available health care services, timeliness of diagnoses, regular and accurate treatment measures, and regular monitoring and follow-up by medical teams.
In the present study, age at diagnosis was found to be inversely related to the risk of death. In other words, the earlier the disease is
diagnosed, the longer patients will survive [20]. The improved survival of patients may be caused by early care procedures. Another protective factor with an inverse relationship with the risk of death was found to be the initiation of deferoxamine therapy. The early initiation of deferoxamine therapy reduces damage to the body organs and thereby prolongs survival [34].
The substantial sample size of 5,491, the nationwide coverage, and the investigation of all the existing records in the examined cities are strengths of this study. The main limitations were incomplete records (especially in Iranshahr), which caused missing data, difficulty accessing the records of deceased patients, and the geographical dispersion of the selected areas of study. Another point that should be considered in the interpretation and application of our results is that some patients with health records in Tehran appeared to have been residents of other cities, such as Sari and Bandar-e-Abbas (Hormozgan), which may have caused repeated entry and analysis of certain individuals’ details. Furthermore, regarding the study of medical records from hospitals, the possibility of selection bias must be considered when interpreting the results. According to the results obtained, the survival rate was 50% by age 55. The overall mean survival of patients was 52.42 years, and the mean survival of patients with TM was 50.07 years. Patients living in Tehran survived longer than those in other cities, and the patients Iranshahr and Zahedan had an unfavorable lifespan. Gender was found to affect the risk of death, with men having a 45% higher risk of death than women. The risk of death was also 4.22 times higher in patients with TM than in those with the sickle form of the disease. A higher level of education, women gender, being married as opposed to being single, and living in metropolises (due to the better healthcare services) increased patient survival.

The authors have no conflicts of interest to declare for this study.

Figure 1.
The selected provinces of Iran included in this study (name of provinces, sample size, and survival rate).
Figure 2.
The survival curve of patients born before and after 1971.
Figure 3.
Kaplan-Meier survival estimates by (A) city and (B) different forms of thalassemia.
Table 1.
The patients’ descriptive data by form of thalassemia
Variables Type of beta-thalassemia
Major Intermedia Sickle Unknown cases1
Age (yr) 21.56±10.28 30.72±11.52 25.30±11.44 24.88±12.58 23.50±11.24
 Men 1,957 (51.1) 445 (47.0) 39 (44.3) 206 (49.8) 2,647 (50.1)
 Women 1,876 (48.9) 501 (53.0) 49 (55.7) 208 (50.2) 2,634 (49.9)
 Tehran 1,695 (43.1) 694 (69.5) 40 (44.9) 144 (61.7) 2,717 (49.5)
 Sari 470 (11.9) 125 (12.5) - 144 (30.8) 739 (13.5)
 Iranshahr 573 (14.6) - - 26 (5.6) 599 (10.9)
 Zahedan 613 (15.6) 4 (0.4) - 4 (0.9) 621 (11.3)
 Hormozgan 585 (14.9) 176 (17.6) 49 (55.1) 5 (1.0) 815 (14.8)
 Illiterate 971 (27.0) 60 (6.7) 8 (9.5) 52 (18.4) 1,091 (40.0)
 <Diploma 1,430 (39.7) 367 (41.2) 51 (60.7) 99 (35.0) 1,947 (20.5)
 Diploma4 652 (18.1) 256 (28.7) 18 (21.4) 69 (24.4) 995 (20.5)
 >Diploma 548 (15.2) 208 (23.3) 7 (8.3) 63 (22.3) 826 (17.0)
 Married 427 (14.4) 304 (33.6) 21 (26.9) 108 (36.7) 860 (20.2)
 Single 2,534 (85.2) 597 (66.0) 57 (73.1) 186 (63.3) 3,374 (79.4)
 Divorced 12 (0.4) 4 (0.4) - - 16 (0.4)
 Yes 1,299 (53.7) 284 (47.1) 38 (57.6) 45 (45.5) 1,666 (30.3)
 No 1,119 (46.3) 319 (52.9) 28 (42.4) 53 (54.1) 1,519 (27.7)
 Missing 2,306 (42.0)

Values are presented as number (%) or mean±standard deviation.

1 Refers to cases where we could not find the type of thalassemia in medical records.

2 210 patients were missing data for gender.

3 632 patients did not have information about their education level.

4 Subjects who had formal education for 12 years in Iran.

5 1,241 patients were missing data.

6 Patients whose parents were blood relations, apart from the marriage connection.

Table 2.
The life table of thalassemia patients
Age (yr) Living patients (n)1 Proportion of survival at each interval Cumulative proportion of survival at end of the interval
0 5,249 1.00 1.00
5 5,018 1.00 1.00
10 4,573 1.00 0.99
15 4,080 0.98 0.97
20 3,426 0.98 0.95
25 2,632 0.97 0.92
30 1,549 0.95 0.88
35 813 0.95 0.83
40 395 0.95 0.79
45 200 0.93 0.74
50 104 0.92 0.68
55 35 0.75 0.51

1 Number of people who were alive at each defined time period.

Table 3.
Mean and median survival by demographic factors
Variables Mean survival
Median survival
Survival estimate 95% CI
Survival estimate 95% CI
Type of thalassemia <0.001
 Major 50.07 48.54 51.60 57.00 51.32 62.67
 Intermediate 56.59 55.65 57.52 55.00 NA
 Sickle 53.10 50.54 55.66 55.00 NA
 Not defined 46.26 43.08 49.44 49 .00 NA
Residence (city) <0.001
 Tehran 54.10 53.22 54.97 55.00 NA
 Mazandaran 47.28 45.61 48.95 54.00 51.62 56.37
 Bandar-e-Abbas 42.21 40.82 43.60 45.00 NA
 Zahedan 33.59 30.55 36.63 32.00 30.74 33.25
 Iranshahr 30.23 29.34 31.11 30.00 NA
Gender 0.001
 Men 51.47 50.33 52.01 NA
 Women 53.49 52.39 54.58 NA
Total 52.42 51.61 53.23 58.00 NA -

CI, confidence interval; LL, lower limit; UL, upper limit; NA, not applicable (since censored data).

Table 4.
Summary associations with incident death among thalassemia patients
Variables HR (95% CI) p-value Adjusted HR (95% CI)1 p-value
Age of diagnosis 0.99 (0.98, 0.99) <0.001 1.00 (1.00, 1.00) 0.89
Age of starting chelation 1.00 (0.99, 1.00) <0.001 1.00 (1.00, 1.00) 0.93
Type of thalassemia
 Sickle beta thalassemia 1.00 (reference) 1.00 (reference)
 Major 4.22 (1.05, 17.01) 0.04 2.40 (0.14, 40.00) 0.53
 Intermediate 0.77 (0.18, 3.27) 0.70 1.20 (0.15, 9.60) 0.84
 Not defined 7.90 (1.92, 33.00) 0.004 3.80 (0.52, 28.40) 0.18
 Tehran 1.00 (reference) 1.00 (reference) -
 Sari (Mazandaran) 3.30 (2.59, 4.25) <0.001 0.60 (0.20, 2.10) 0.48
 Hormozgan 4.00 (2.99, 5.48) 5.30 (3.10, 9.05) <0.001
 Iranshahr 5.40 (3.20, 9.18) 5.70 (2.60, 12.00) <0.001
 Zahedan 6.20 (4.33, 9.03) 5.20 (2.80, 9.60) <0.001
 Women 1.00 (reference) 1.00 (reference)
 Men 1.40 (1.17, 1.81) 0.001 1.20 (0.82, 1.70) 0.31
Education level
 Illiterate 2.49 (1.09, 5.66) 0.03 0.80 (0.23, 3.20) 0.84
 < Diploma 3.80 (2.36, 6.19) <0.001 2.30 (1.20, 4.50) 0.01
 Diploma2 1.80 (1.09, 3.14) 0.02 1.30 (0.66, 2.68) 0.41
 >Diploma 1.00 (reference) 1.00 (reference) -
 Married 1.00 (reference) 1.00 (reference)
 Single 3.80 (2.52, 5.79) <0.001 2.80 (1.40, 5.60) 0.002
 Divorced NA 0.90 NA -

HR, hazard ratio; CI, confidence interval; NA, not applicable (since the corresponding category did not include enough subjects).

1 The multivariate analysis included all variables listed in Table 3. The enter method was selected for estimating the HR.

2 Subjects who had 12 years of formal education in Iran.

  • 1. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97:3411-3416.ArticlePubMed
  • 2. Olivieri NF. The β-thalassemias. N Engl J Med 1999;341:99-109.ArticlePubMed
  • 3. Haddad A, Tyan P, Radwan A, Mallat N, Taher A. β-thalassemia intermedia: a bird’s-eye view. Turk J Haematol 2014;31:5-16.ArticlePubMedPMC
  • 4. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-1146.ArticlePubMed
  • 5. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. Ann N Y Acad Sci 2005;1054:40-47.ArticlePubMed
  • 6. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89:1187-1193.PubMed
  • 7. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005;1054:445-450.ArticlePubMed
  • 8. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2:27-30.ArticlePubMed
  • 9. Bazrgar M, Peiravian F, Abedpour F, Karimi M. Causes for hospitalization and death in Iranian patients with β-thalassemia major. Pediatr Hematol Oncol 2011;28:134-139.ArticlePubMed
  • 10. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007;138:291-304.ArticlePubMed
  • 11. Aessopos A, Farmakis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005;127:1523-1530.ArticlePubMed
  • 12. Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006;37:12-20.ArticlePubMed
  • 13. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica 2007;92:658-665.ArticlePubMed
  • 14. Bannerman RM, Keusch G, Kreimer-Birnbaum M, Vance VK, Vaughan S. Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria. Am J Med 1967;42:476-486.ArticlePubMed
  • 15. Rafsanjani KA, Mafi N, Tafreshi RI. Complications of β-thalassemia intermedia in Iran during 1996–2010 (single-center study). Pediatr Hematol Oncol 2011;28:497-508.ArticlePubMed
  • 16. Haghpanah S, Ramzi M, Zakerinia M, Nourani Khojasteh H, Haghshenas M, Rezaei N, et al. Epidemiology of hemoglobinopathies and thalassemias in individuals referred to the haematology research centre, Shiraz University of Medical Sciences, Shiraz, Iran from 2006 to 2011. Hemoglobin 2014;38:287-288.ArticlePubMed
  • 17. Habibzadeh F, Yadollahie M, Merat A, Haghshenas M. Thalassemia in Iran; an overview. Arch Iran Med 1998;1:27-33.
  • 18. Saleh-Gohari N, Bazrafshani M. Distribution of β-globin gene mutations in thalassemia minor population of Kerman Province, Iran. Iran J Public Health 2010;39:69-76.PubMedPMC
  • 19. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005;1054:18-24.ArticlePubMed
  • 20. Kosaryan M, Vahidshahi K, Karami H, Forootan MA, Ahangari M. Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin 2007;31:453-462.ArticlePubMed
  • 21. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassemia in Iran: epidemiology, prevention, and management. J Pediatr Hematol Onc 2007;29:233-238.Article
  • 22. Kazemnejad A, Mehrabi YE, Al Moazez M, Yavarian M. Survival analysis of patients suffering from thalassemia in Hormozgan province. Modares J Med Sci (Pathobiol) 2002;4:173-180 (Perisian).
  • 23. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11.ArticlePubMedPMCPDF
  • 24. Joly P, Pondarre C, Badens C. Beta-thalassemias: molecular, epidemiological, diagnostical and clinical aspects. Ann Biol Clin (Paris) 2014;72:639-668.ArticlePubMed
  • 25. Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, et al. Hydroxyurea in thalassemia intermedia—a promising therapy. Ann Hematol 2005;84:441-446.ArticlePubMed
  • 26. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al. Survival and disease complications in thalassemia major. Ann N Y Acad Sci 1998;850:227-231.ArticlePubMed
  • 27. Khoei RA, Bakhshi E, Azarkeivan A, Biglarian A. Survival analysis of patients with thalassemia major using parametric and semiparametric survival models. J Health Adm 2015;18:82-91 (Persian).
  • 28. Zamani R, Khazaei S, Rezaeian S. Survival analysis and its associated factors of beta thalassemia major in Hamadan province. Iran J Med Sci 2015;40:233-239.PubMedPMC
  • 29. Rajaeefard A, Hajipour M, Tabatabaee HR, Hassanzadeh J, Rezaeian S, Moradi Z. Analysis of survival data in thalassemia patients in Shiraz, Iran. Epidemiol Health 2015;37:e2015031.ArticlePubMedPMC
  • 30. Roudbari M, Soltani-Rad M, Roudbari S. The survival analysis of beta thalassemia major patients in South East of Iran. Saudi Med J 2008;29:1031-1035.PubMed
  • 31. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.ArticlePubMed
  • 32. Chern JP, Su S, Lin KH, Chang SH, Lu MY, Jou ST, et al. Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan. Pediatr Blood Cancer 2007;48:550-554.ArticlePubMed
  • 33. Latifi SM, Zandian K. Survival analysis of β-thalassemia major patients Khouzestan province referring to Shafa hospital. Sci Med J 2010;9:83-92 (Persian).
  • 34. Modell B, Letsky EA, Flynn DM, Peto R, Weatherall DJ. Survival and desferrioxamine in thalassaemia major. Br Med J (Clin Res Ed) 1982;284:1081-1084.ArticlePubMedPMC

Figure & Data



    Citations to this article as recorded by  
    • Beta thalassemia: Looking to the future, addressing unmet needs and challenges
      Michael Angastiniotis
      Annals of the New York Academy of Sciences.2024; 1532(1): 63.     CrossRef
    • Predicting factors of survival rates among alpha- and beta-thalassemia patients: a retrospective 10-year data analysis
      Kunapa Iam-arunthai, Tawatchai Suwanban, Pravinwan Thungthong, Supat Chamnanchanunt, Suthat Fucharoen
      Frontiers in Hematology.2024;[Epub]     CrossRef
    • Investigating the effectiveness of Case‐Based Technology‐Enhanced workshops (e‐Flipped vs. Online) among health worker nurses during the COVID‐19 pandemic
      Nahid Zarifsanaiey, Roghaye Sajjadian, Zahra Karimian, Laleh Khojasteh, Hadi Raeisi Shahraki
      Nursing Open.2023; 10(4): 2329.     CrossRef
    • The Need for Translational Epidemiology in Beta Thalassemia Syndromes
      Soteris Soteriades, Michael Angastiniotis, Dimitrios Farmakis, Androulla Eleftheriou, Aurelio Maggio
      Hematology/Oncology Clinics of North America.2023; 37(2): 261.     CrossRef
    • Desire for biological parenthood and patient counseling on the risk of infertility among adolescents and adults with hemoglobinopathies
      Anne‐Catherine Radauer‐Plank, Tamara Diesch‐Furlanetto, Monika Schneider, Greta Sommerhäuser, Lucía Alácan Friedrich, Vivienne Salow, Jill Dülberg, Miriam Diepold, Alicia Rovó, Linet Muthoni Njue, Beatrice Drexler, Laura Infanti, Sabine Kroiss, Ramona Mer
      Pediatric Blood & Cancer.2023;[Epub]     CrossRef
    • Systematic Literature Review Shows Gaps in Data on Global Prevalence and Birth Prevalence of Sickle Cell Disease and Sickle Cell Trait: Call for Action to Scale Up and Harmonize Data Collection
      Raffaella Colombatti, Inga Hegemann, Morten Medici, Camilla Birkegård
      Journal of Clinical Medicine.2023; 12(17): 5538.     CrossRef
    • Economic burden of adult patients with β-thalassaemia major in mainland China
      Xuemei Zhen, Jing Ming, Runqi Zhang, Shuo Zhang, Jing Xie, Baoguo Liu, Zijing Wang, Xiaojie Sun, Lizheng Shi
      Orphanet Journal of Rare Diseases.2023;[Epub]     CrossRef
    • Accelerated atherosclerosis in beta-thalassemia
      Julian Hurtado, Hassan Sellak, Giji Joseph, Caitlin V. Lewis, Crystal R. Naudin, Sergio Garcia, James Robert Wodicka, David R. Archer, W. Robert Taylor
      American Journal of Physiology-Heart and Circulatory Physiology.2023; 325(5): H1133.     CrossRef
    • Prevalence and risk factors of fractures in transfusion dependent thalassemia – A Hong Kong Chinese population cohort
      Samantha Lai Ka Lee, Raymond Siu Ming Wong, Chi Kong Li, Wing Kwan Leung
      Endocrinology, Diabetes & Metabolism.2022;[Epub]     CrossRef
    • Estimation of the prevalence of Hemoglobinopathies in Erbil governorate, Kurdistan region of Iraq
      SarkarS Aziz, BahraK Hamad, HeroO Hamad, MuzhdaI Qader, EmanN Ali, RayanH Muhammed, MudhirSabir Shekha
      Iraqi Journal of Hematology.2022; 11(1): 19.     CrossRef
    • Thalassaemia
      Antonis Kattamis, Janet L Kwiatkowski, Yesim Aydinok
      The Lancet.2022; 399(10343): 2310.     CrossRef
    • Bone Mineral Density, Serum Calcium, and Vitamin D Levels in Adult Thalassemia Major Patients: Experience From a Single Center in Eastern India
      Soumya Santra, Kunal Sharma, Ipsita Dash, Shaikat Mondal, Himel Mondal
      Cureus.2022;[Epub]     CrossRef
    • Thalassemia Intermedia: Chelator or Not?
      Yen-Chien Lee, Chi-Tai Yen, Yen-Ling Lee, Rong-Jane Chen
      International Journal of Molecular Sciences.2022; 23(17): 10189.     CrossRef
    • The Outcomes of Patients with Haemoglobin Disorders in Cyprus: A Joined Report of the Thalassaemia International Federation and the Nicosia and Paphos Thalassaemia Centres (State Health Services Organisation)
      Michael Angastiniotis, Soteroula Christou, Annita Kolnakou, Evangelia Pangalou, Irene Savvidou, Dimitrios Farmakis, Androulla Eleftheriou
      Thalassemia Reports.2022; 12(4): 143.     CrossRef
    • Abnormal diastolic function and Global longitudinal strain in patients with Thalassemia Major on long term chelation therapy
      Sunil K. Nadar, Shahina Daar, Wael A. Abdelmottaleb, Muhammad M. Shaikh, Hafsa Al Mahrouqi, Majida Al-Raiisi, Moez Hassan, Badar Al Rawahi, Sarah Al Rahbi
      The International Journal of Cardiovascular Imaging.2021; 37(2): 643.     CrossRef
    • The effect of curcumin on serum copper, zinc, and zinc/copper ratio in patients with β-thalassemia intermedia: a randomized double-blind clinical trial
      Mohammadreza Saeidnia, Peyman Nowrouzi-Sohrabi, Mehran Erfani, Pooria Fazeli, Gholamhossein Tamaddon, Mehran Karimi
      Annals of Hematology.2021; 100(3): 627.     CrossRef
    • The Prevention of Thalassemia Revisited: A Historical and Ethical Perspective by the Thalassemia International Federation
      Michael Angastiniotis, Mary Petrou, Dimitrios Loukopoulos, Bernadette Modell, Dimitrios Farmakis, Panos Englezos, Androulla Eleftheriou
      Hemoglobin.2021; 45(1): 5.     CrossRef
    • Developing a databank for multiple transfusion patients: Rh antigen and phenotype distribution among 3000 regular blood donors in Iran
      Zahra Bakhshandeh, Naser Amirizadeh, Mahtab Maghsoodlu, Arezoo Oodi, Amirali Naghi, Ali Arab Khazaeli, Azita Azarkeivan
      Transfusion and Apheresis Science.2021; 60(3): 103124.     CrossRef
    • Thalassemia-Beta major-Case report
      Ambarkova Vesna, Krmzova Tina, Nonkulovski Zoran
      Archives of Hematology Case Reports and Reviews.2021; : 021.     CrossRef
    • An insight into Indonesian current thalassaemia care and challenges
      Pustika Amalia Wahidiyat, Teny Tjitra Sari, Ludi Dhyani Rahmartani, Iswari Setianingsih, Stephen Diah Iskandar, Anastasia Michelle Pratanata, Ivana Yapiy, Mikhael Yosia, Fernando Tricta
      ISBT Science Series.2020; 15(3): 334.     CrossRef


    Epidemiol Health : Epidemiology and Health